← Back to patent-cliff list
CAS 63-05-8
(3aS,3bR,9aR,9bS,11aS)-9a,11a-Dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
Codes: (I)169995-10-a, PRAS-007, PRAS-008, DUTA-026
Application context (from source-drug indications)
ContraceptionDrospirenoneStomatitis, aphthousDrospirenonePremenstrual dysphoric disorderDrospirenonePremenstrual syndromeDrospirenoneDysmenorrhoeaDrospirenoneDepressionDrospirenoneVulvovaginal atrophyPrasteroneAtrophyPrasteroneDyspareuniaPrasteroneBreast cancerPrasteroneVaginal diseasePrasteroneAnal neoplasmPrasteroneBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideUrinary retentionDutasterideBenign prostatic hyperplasiaDutasterideAlopeciaDutasterideAlcohol abuseDutasterideBladder cancerDutasterideProstate cancerDutasteride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Drospirenone | Tier C — Watch / trade | - |
| Prasterone | Tier C — Watch / trade | - |
| Dutasteride/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Dutasteride | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3aS,3bR,9aR,9bS,11aS)-9a,11a-Dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione→(8R,9S,10R,13S,14S)-3-Ethoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-one→3-Ethoxy-16-(phenylsulfinyl)androsta-3,5-dien-17-one→16-(Phenylsulfinyl)androst-4-ene-3,17-dione→Androsta-4,15-diene-3,17-dione→(4aR,4bS,6aS,7aS,8aS,8bR,8cR)-4a,6a-Dimethyl-4,4a,4b,6,6a,7a,8,8a,8b,8c,9,10-dodecahydrocyclopropa[4,5]cyclopenta[1,2-a]phenanthrene-2,7(3H,5H)-dione→(4aR,4bS,6aS,7aS,8aS,8bS,8cR)-4a,6a-Dimethyl-4,4a,4b,6,6a,7a,8,8a,8b,8c-decahydrocyclopropa[4,5]cyclopenta[1,2-a]phenanthrene-2,7(3H,5H)-dione→6beta,7beta,15beta,16beta-Dimethylene-17beta-spirooxiranoandrost-4-en-3-one→Carbethoxyacetic ester→(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-Dimethyl-5',7-dioxospiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolan]-5-ene-4'-carboxylic acid
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol→(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate→(3S,5R,6R,8S,9S,10R,13R,14S,17R)-5,6-dibromo-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate→(3S,5R,6R,8S,9S,10R,13S,14S)-5,6-dibromo-10,13-dimethyl-17-oxohexadecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate→hydrazinecarboxamide hydrochloride→hydrazinecarboxamide hydrochloride→(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→(8R,9S,10R,13S,14S)-10,13-dimethyl-1,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→(8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate→(8R,9S,10R,13S,14S)-10,13-dimethyl-1,2,7,8,9,10,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-yl acetate→(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-ol
(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→3-((3aS,5aS,6R,9aR,9bS)-3a,6-dimethyl-3,7-dioxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid→(4aR,4bS,6aS,9aS,9bR)-4a,6a-dimethyl-3,4,4a,4b,5,6,6a,8,9,9a,9b,10-dodecahydro-1H-indeno[5,4-f]quinoline-2,7-dione→(4aR,4bS,6aS,7R,9aS,9bR)-7-hydroxy-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,9aS,9bS)-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,9,9a,9b,10-dodecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aR,7S,9aS,9bS,11aR)-4a,6a,7-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→2,5-bis(trifluoromethyl)aniline
(8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→3-((3aS,5aS,6R,9aR,9bS)-3a,6-dimethyl-3,7-dioxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid→(4aR,4bS,6aS,9aS,9bR)-4a,6a-dimethyl-3,4,4a,4b,5,6,6a,8,9,9a,9b,10-dodecahydro-1H-indeno[5,4-f]quinoline-2,7-dione→(4aR,4bS,6aS,7R,9aS,9bR)-7-hydroxy-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,9aS,9bS)-4a,6a,7-trimethyl-1,3,4,4a,4b,5,6,6a,9,9a,9b,10-dodecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aR,7S,9aS,9bS,11aR)-4a,6a,7-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid→2,5-bis(trifluoromethyl)aniline
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.